Category

Daily Briefs

Daily Brief Credit: Lucror Analytics – Morning Views Asia and more

By | Credit, Daily Briefs

In today’s briefing:

  • Lucror Analytics – Morning Views Asia


Lucror Analytics – Morning Views Asia

By Trung Nguyen

  • In today’s Morning Views publication we comment on developments of the following high yield issuers: JSW Steel
  • UST yields fell yesterday, led by the front end and belly, as weaker than projected ADP employment data further bolstered Fed easing expectations. The UST curve bull steepened, with the yield on the 2Y UST down 7 bps to 3.54%, while that on the 10Y UST declined 5 bps to 4.10%.
  • Equities climbed for the fourth day, with the market remaining upbeat despite the US government shutdown. The S&P 500 and Nasdaq rose 0.3% and 0.4% to 6,711 and 22,755, respectively.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Jardine Matheson Holdings, LS Marine Solution, Hindustan Aeronautics , Daiseki Eco. Solution, Vicor Corp, Cosin Solar Technology Co, Chorus Aviation, ICTSI, Deutsche Post, Omni-Lite Industries Canada and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Jardine Matheson (JML SP): Additional Office Recycling Speculated
  • Potential Additions and Deletions to KOSDAQ150 in December 2025
  • Quiddity Leaderboard NIFTY Mar26: Hindustan Aeronautics and Adani Enterprises Close to the Borders
  • Daiseki Eco. Solution (1712 JP): Daiseki (9793 JP)’s Tender Offer at JPY1,850
  • Primer: Vicor Corp (VICR US) – Oct 2025
  • Cosin Solar Technology Co Pre-IPO Tearsheet
  • Current Active Quick Pitches: Mergers, Acquisitions, Tender Offers, and More
  • ICTSI (ICT PM): Terminal Operator, Serial Grower With Pricing Power, 20% ROCE, 30% Net Margins
  • What’s News in Amsterdam – 2 October (JET/Prosus | TomTom | Triodos Bank | DHL | E-com & Logistics)
  • Omni-Lite Industries Canada (OML.) – Wednesday, Jul 2, 2025


Jardine Matheson (JML SP): Additional Office Recycling Speculated

By David Blennerhassett

  • The prior MO for the Jardines group was never sell your commercial buildings. This year marks a paradigm shift in that line of thinking. 
  • First Hongkong Land (HKL SP) sold nine floors of One Exchange Square to HKEX (388 HK). The first such sale since 1988.
  • Now Mandarin Oriental (MAND SP) is negotiating the sale of “certain office space” at One Causeway Bay. Jardine Matheson (JM SP)‘s NAV discount and implied stub are at 12-month lows/highs.

Potential Additions and Deletions to KOSDAQ150 in December 2025

By Douglas Kim

  • In this insight, we provide an early look at the potential additions and deletions to KOSDAQ150 rebalance in December 2025.
  • The 7 potential additions are up on average 164% YTD. The 8 potential deletion candidates are down on average 25.1% YTD. KOSDAQ is up 26% YTD.
  • The average market cap of the 7 potential additions is 1,515 billion won. The average market cap of the 8 potential deletion candidates is 275 billion won.

Quiddity Leaderboard NIFTY Mar26: Hindustan Aeronautics and Adani Enterprises Close to the Borders

By Janaghan Jeyakumar, CFA

  • NIFTY 50 represents the 50 largest stocks listed in the National Stock Exchange (NSE) of India and the NIFTY Next 50 index tracks the next 50 largest names.
  • In this insight, we take a look at the names leading the race to become ADDs/DELs for these indices during the March 2026 index rebal event.
  • We see no changes for NIFTY 50 and three changes for NIFTY 100 (which would result in similar changes to NIFTY Next 50).

Daiseki Eco. Solution (1712 JP): Daiseki (9793 JP)’s Tender Offer at JPY1,850

By Arun George

  • Daiseki Eco. Solution (1712 JP) has recommended a tender offer from Daiseki Co Ltd (9793 JP) at JPY1,850, a 54.3% premium to the last close.
  • The offer is attractive as it is above the midpoint of the target IFA DCF valuation range and represents a three-year high. 
  • The low required minority tendering rate facilitates completion. The tender runs from 3 October to 17 November.  

Primer: Vicor Corp (VICR US) – Oct 2025

By αSK

  • Vicor is a highly innovative designer and manufacturer of high-density, high-efficiency modular power solutions, positioning it as a key enabler for demanding applications in artificial intelligence (AI), high-performance computing (HPC), automotive, and aerospace.
  • The company’s proprietary technologies and vertical integration provide a technological moat; however, the business faces significant risks from customer concentration, intense competition from larger semiconductor players, and market cyclicality.
  • Financial performance has been volatile, with recent margin compression and analyst downgrades creating uncertainty, yet the company maintains a strong balance sheet and is poised to capitalize on long-term secular growth trends in electrification and data center power demands.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Cosin Solar Technology Co Pre-IPO Tearsheet

By Hong Jie Seow

  • Cosin Solar Technology Co (SUPCOZ CH) is looking to raise about US$100m in its upcoming Hong Kong IPO. The deal will be run by China Securities International.
  • Cosin Solar Technology Co. (CST) is a Chinese company specializing in concentrated solar power (CSP) solutions, particularly molten salt tower systems. 
  • The company’s main business lies in providing the collector system and other core sub-systems essential for constructing large-scale CSP plants.

Current Active Quick Pitches: Mergers, Acquisitions, Tender Offers, and More

By Special Situation Investments

  • Chorus Aviation is repurchasing 8% of shares at C$23.00–C$25.00, offering C$45 risk-free upside; tender expires November 10.
  • STAAR Surgical’s largest shareholder opposes Alcon’s $28/share acquisition, potentially forcing a higher bid before October 23 meeting.
  • Forian’s $2.10/share go-private proposal by a founder-led consortium is under review, with shares trading at offer price.

ICTSI (ICT PM): Terminal Operator, Serial Grower With Pricing Power, 20% ROCE, 30% Net Margins

By Sameer Taneja

  • The ICTSI (ICT PM), the largest container port terminal operator in the Philippines (also with a global presence), trades at 17x PE, 9x EV-EBITDA trailing, with a dividend yield of ~3.2%.
  • The company operates container terminals efficiently, boasting EBITDA and net margins of 65% and 31%, respectively, and improving ROCE metrics exceeding 20% (averaging 14% over the past decade).
  • The company demonstrates strong pricing power in a challenging global environment, presenting an opportunity to explore further if additional market corrections occur.

What’s News in Amsterdam – 2 October (JET/Prosus | TomTom | Triodos Bank | DHL | E-com & Logistics)

By The IDEA!

  • In this edition: • Just Eat TakeAway.com | Prosus declares offer unconditional • TomTom | expands its partnership with Hyundai AutoEver • Triodos Bank | closed proposed settlement deal with 82.4% of its depository receipt holders • DHL | buys out its APM partner in Poland • E-commerce & Logistics | Greek e-com association calls for levy on Chinese parcels

Omni-Lite Industries Canada (OML.) – Wednesday, Jul 2, 2025

By Value Investors Club (VIC)

Key points (machine generated)

  • Omni-Lite is a specialized components manufacturer focused on the aerospace market with facilities in California, New Hampshire, and Ontario.
  • The company operates three business units: a metal forging facility, an electronics division acquired in 2018, and a metal castings operation acquired in 2022.
  • Under CEO Dave Robbins, who owns 3.8% of the company, Omni-Lite is positioned for growth in unique, low-volume parts, making it an attractive investment opportunity.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: HBM Stocks Will Keep Running (Micron and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • HBM Stocks Will Keep Running (Micron, SK Hynix), It’s Just the Beginning
  • Gap Trade Opportunities in Korean Prefs Vs Common Share Pairs in 4Q 2025
  • A Contrarian View on New World: Market Is Forward-Looking, Bet on Leveraged Play in Rate Cut Cycle
  • Firebird Management’s Steve Gorelik’s Molina Healthcare Bull Thesis $MOH
  • Taiwan Tech Weekly: OpenAI to Consume Nearly Half of Global DRAM; Why TSMC 2nm Will Be A Blockbuster
  • The United Laboratories International Holdings (TUL) Ltd (3933 HK) – Retain Buy
  • The Beat Ideas: ADF Foods – Can an Export-Heavy Model Withstand Tariff Pressures?
  • Primer: Vicor Corp (VICR US) – Oct 2025
  • Primer: BigBear.ai Holdings (BBAI US) – Oct 2025
  • Primer: Mysore Paper Mills (MSPM IN) – Oct 2025


HBM Stocks Will Keep Running (Micron, SK Hynix), It’s Just the Beginning

By Nicolas Baratte

  • SK Hynix and Micron stocks were lagging TSMC and Nvidia as it took ~2 years for HBM to suck up enough Commodity DRAM capacity to stabilize the Commodity market
  • That’s now done, we’re just at the beginning of spectacular HBM growth for at least 2 more years. The reasons are known: density increases, speed increases, dies thinner…
  • Stocks: keep or buy Micron and SK Hynix. Samsung remains unattractive imo

Gap Trade Opportunities in Korean Prefs Vs Common Share Pairs in 4Q 2025

By Douglas Kim

  • In this insight, we discuss numerous gap trade opportunities involving Korean preferred and common shares in 4Q 2025.
  • The preferred companies’ share price discount (relative to the common shares) on the 27 pairs below was 36% at the end of September 2025.
  • On a longer timeframe (3-5 years), this discount could narrow further to the 20-25% range, which provides additional opportunities for the Korean preferred shares to further make relative gains.

A Contrarian View on New World: Market Is Forward-Looking, Bet on Leveraged Play in Rate Cut Cycle

By Jacob Cheng

  • New World announced FY25 results, market reaction was initially negative, due to losses to shareholders.  Stock was down 10% post open but rebounded quickly to recover all the losses
  • However, we think the market has neglected the other positives: strong contract sales, resilient IP earnings, improved total debt, stabilized gearing and lower borrow cost
  • Market is forward-looking, we think NWD, as a leveraged play, will benefit the most in rate cut cycle.  At current valuation (0.12x PB) – we continue to stay bullish

Firebird Management’s Steve Gorelik’s Molina Healthcare Bull Thesis $MOH

By Yet Another Value Podcast

Molina Healthcare is a managed care organization specializing in Medicaid plans, with a market share of about 6% of the US population in Medicaid

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Taiwan Tech Weekly: OpenAI to Consume Nearly Half of Global DRAM; Why TSMC 2nm Will Be A Blockbuster

By Vincent Fernando, CFA

  • OpenAI, Samsung & SK Hynix Lock In Memory Pact — Taiwan Next Stop
  • MediaTek’s Major ASIC Ambitions Face Delays from Some Key Clients
  • TSMC: New Signals Underscore N2’s Rise as a Blockbuster Node 

The United Laboratories International Holdings (TUL) Ltd (3933 HK) – Retain Buy

By Avien Pillay

  • Despite its 96% price appreciation since our initiation, United Laboratories is still trading on a 8.7 FPE, and a 5.5 EV/EVITDA.
  • A US FDA GLP-1 approval and a potential $ 1.8bn deal with Novo Nordisk demonstrates its successful diabetes and obesity strategy.
  • With over 80 drugs in the pipeline to be delivered over the next five years, we believe that TUL is about to experience a very material increase in topline growth.

The Beat Ideas: ADF Foods – Can an Export-Heavy Model Withstand Tariff Pressures?

By Nimish Maheshwari

  • ADF Foods is shifting from an agency-based distribution model to a brand-led, in-house manufacturing approach, focusing on the U.S. frozen food segment to improve margins and supply control.
  • This strategic pivot enhances margin stability, mitigates raw material and geopolitical risks, and deepens market penetration in mainstream international retail, positioning ADF for sustainable long-term growth and profitability.
  • Market focus should move from export volatility to ADF’s brand premiumization and successful US greenfield execution, the key drivers of sustainable growth and long-term re-rating.

Primer: Vicor Corp (VICR US) – Oct 2025

By αSK

  • Vicor is a highly innovative designer and manufacturer of high-density, high-efficiency modular power solutions, positioning it as a key enabler for demanding applications in artificial intelligence (AI), high-performance computing (HPC), automotive, and aerospace.
  • The company’s proprietary technologies and vertical integration provide a technological moat; however, the business faces significant risks from customer concentration, intense competition from larger semiconductor players, and market cyclicality.
  • Financial performance has been volatile, with recent margin compression and analyst downgrades creating uncertainty, yet the company maintains a strong balance sheet and is poised to capitalize on long-term secular growth trends in electrification and data center power demands.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: BigBear.ai Holdings (BBAI US) – Oct 2025

By αSK

  • BigBear.ai is a specialized provider of AI-powered decision intelligence solutions, with a primary focus on the U.S. defense, intelligence, and homeland security sectors. Its established relationships and expertise in these niche markets provide a competitive advantage.
  • The company is in a high-growth industry but faces significant financial headwinds. It has a history of substantial net losses and negative operating cash flow, indicating a high-risk profile. Revenue growth has been inconsistent, with recent quarterly performance showing a year-over-year decline.
  • Future success is heavily dependent on securing large-scale government contracts and successfully expanding into the commercial sector to diversify revenue. The company’s strong balance sheet, with a significant cash position, is intended to fund investments to capture these opportunities, but execution remains a key uncertainty.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Mysore Paper Mills (MSPM IN) – Oct 2025

By αSK

  • Non-Operational Entity in Financial Distress: Mysore Paper Mills (MSPM) has ceased all core manufacturing operations, with paper production halted in 2015 and its sugar division in 2016. The company is characterized by a prolonged history of substantial financial losses, negative margins, and a complete erosion of net worth, rendering it a financially unviable entity in its current state.
  • Government-Led Revival Efforts via Privatization: The Government of Karnataka (GoK), the majority shareholder, has deemed a public sector revival unfeasible and is actively pursuing leasing the company’s assets and operations to a private entity. However, multiple tender attempts since 2017 have failed to attract bidders, highlighting significant challenges and perceived risks by potential investors.
  • High Uncertainty Against a Favorable Industry Backdrop: The company’s future is entirely contingent on the success of the government’s leasing strategy, which faces high uncertainty. This contrasts with the positive outlook for the broader Indian paper industry, which is experiencing robust growth driven by demand in packaging and education. Any potential value in MSPM lies in its physical assets and the speculative possibility of a successful operational turnaround under a new private operator.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: LS Marine Solution, Samsung Electronics Pref Shares and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Potential Additions and Deletions to KOSDAQ150 in December 2025
  • Gap Trade Opportunities in Korean Prefs Vs Common Share Pairs in 4Q 2025


Potential Additions and Deletions to KOSDAQ150 in December 2025

By Douglas Kim

  • In this insight, we provide an early look at the potential additions and deletions to KOSDAQ150 rebalance in December 2025.
  • The 7 potential additions are up on average 164% YTD. The 8 potential deletion candidates are down on average 25.1% YTD. KOSDAQ is up 26% YTD.
  • The average market cap of the 7 potential additions is 1,515 billion won. The average market cap of the 8 potential deletion candidates is 275 billion won.

Gap Trade Opportunities in Korean Prefs Vs Common Share Pairs in 4Q 2025

By Douglas Kim

  • In this insight, we discuss numerous gap trade opportunities involving Korean preferred and common shares in 4Q 2025.
  • The preferred companies’ share price discount (relative to the common shares) on the 27 pairs below was 36% at the end of September 2025.
  • On a longer timeframe (3-5 years), this discount could narrow further to the 20-25% range, which provides additional opportunities for the Korean preferred shares to further make relative gains.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Macro: Australian Equities: Where are we now and more

By | Daily Briefs, Macro

In today’s briefing:

  • Australian Equities: Where are we now, and what’s next?
  • Gold Mania, Niobium Dreams, and Antimony Nightmares (Datt)
  • EA: Rounding Jobs For Migrants
  • Walker’s Weekly: Dr. Jim’s Summary of Key Global Macro Developments – 3 October 2025
  • Oil futures: Crude slides as oversupply concerns offset geopolitics


Australian Equities: Where are we now, and what’s next?

By MAGELLAN – IN THE KNOW

  • Australian economy remains sluggish, but some positives include recovery in small caps and resilience of Australian consumers
  • Market volatility and narrow leadership driving unhappiness among active investors
  • Resilience of Aussie consumer and strong retail results stood out in recent reporting season, with small caps and US housing exposure also notable themes

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Gold Mania, Niobium Dreams, and Antimony Nightmares (Datt)

By Money of Mine

  • US monetary policy is accommodative and markets are buoyant, especially in commodities
  • Investors need to be cautious about being overly bullish in current environment
  • Similarities seen with 2006-2007 period, particularly in disruptions in copper supply and new technologies in metal recovery; investors should be wary of hype and potential risks involved

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


EA: Rounding Jobs For Migrants

By Phil Rush

  • A surprise rise in EA unemployment reflects rounding rather than alarming weakness, with labour supply and demand still surging. Finland’s woes are more idiosyncratic.
  • Supply has trended much faster post-pandemic, sustaining demand at its old trend without extreme capacity constraints. Migration has more than accounted for the rise.
  • Ukrainians are dominating the flow and complicating the read through to disinflationary spare capacity. Wage growth is an even more critical signal when supply is uncertain.

Walker’s Weekly: Dr. Jim’s Summary of Key Global Macro Developments – 3 October 2025

By Dr. Jim Walker

  • The US shutdown remains political theatre, with no real progress on deficit reduction or fiscal reform.

  • Thailand’s baht is Asia’s strongest currency, but structural issues and weak growth outlook persist despite strong external balances.

  • Regional PMIs show a mixed picture, with Thailand surprisingly strong, Taiwan weak, and India continuing to lead.


Oil futures: Crude slides as oversupply concerns offset geopolitics

By Quantum Commodity Intelligence

  • Crude oil futures were sliding lower Thursday as benchmarks racked up a fourth consecutive retreat of the week, coming amid expectations of a further OPEC+ hike offsetting heightened geopolitical tensions.
  • Front-month Dec25 ICE Brent futures were trading at $64.16/b (2035 BST) versus Wednesday’s settle of $65.35/b, while Nov25 NYMEX WTI was at $60.57/b against a previous close of $61.78/b.
  • Briefings from OPEC+ delegates over the last few days have wiped out the previous week’s healthy gains, with the group now expected to bring back a second tranche of voluntary cuts at a quicker-than-expected pace.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Energy/Materials: Mysore Paper Mills, Weebit Nano Ltd, Regulus Resources, Spanish Mountain Gold, Exploits Discovery, JSW Steel Ltd, Evolution Petroleum, Crude Oil and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • Primer: Mysore Paper Mills (MSPM IN) – Oct 2025
  • Primer: Weebit Nano Ltd (WBT AU) – Oct 2025
  • REG: A Tier-1 Copper-Gold Project in the Making
  • Spanish Mountain Gold Ltd – Mining Monthly: September Edition
  • Exploits Discovery Corp – Q3/25 Recap: All Our Research in One Place!
  • Lucror Analytics – Morning Views Asia
  • EPM: Latest SCOOP/STACK Acquisition Supports Consistent Dividend Philosophy
  • Oil futures: Crude slides as oversupply concerns offset geopolitics


Primer: Mysore Paper Mills (MSPM IN) – Oct 2025

By αSK

  • Non-Operational Entity in Financial Distress: Mysore Paper Mills (MSPM) has ceased all core manufacturing operations, with paper production halted in 2015 and its sugar division in 2016. The company is characterized by a prolonged history of substantial financial losses, negative margins, and a complete erosion of net worth, rendering it a financially unviable entity in its current state.
  • Government-Led Revival Efforts via Privatization: The Government of Karnataka (GoK), the majority shareholder, has deemed a public sector revival unfeasible and is actively pursuing leasing the company’s assets and operations to a private entity. However, multiple tender attempts since 2017 have failed to attract bidders, highlighting significant challenges and perceived risks by potential investors.
  • High Uncertainty Against a Favorable Industry Backdrop: The company’s future is entirely contingent on the success of the government’s leasing strategy, which faces high uncertainty. This contrasts with the positive outlook for the broader Indian paper industry, which is experiencing robust growth driven by demand in packaging and education. Any potential value in MSPM lies in its physical assets and the speculative possibility of a successful operational turnaround under a new private operator.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Weebit Nano Ltd (WBT AU) – Oct 2025

By αSK

  • Weebit Nano is a pre-revenue semiconductor company developing a next-generation non-volatile memory (NVM) technology called Resistive RAM (ReRAM).
  • The company’s primary business model is licensing its ReRAM intellectual property (IP) to semiconductor foundries and integrated device manufacturers (IDMs).
  • Weebit’s ReRAM technology aims to be a successor to flash memory, offering significant improvements in performance, power consumption, and endurance, particularly for applications in IoT, AI, and automotive sectors.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


REG: A Tier-1 Copper-Gold Project in the Making

By Atrium Research

  • Regulus 100% owns the AntaKori Copper-Gold Project in northern Peru, with a high-grade, low-strip, and at-surface resource of 8.0Blbs CuEq.
  • The project neighbours Coimolache’s Tantahuatay Oxide Gold Mine which REG has a collaboration agreement to assess the potential combined development of the much larger Cu-Au sulphide system lying beneath the Oxide Gold Mine and across both properties.
  • The management team and board, including CEO John Black, largely come from Antares Minerals, where they discovered the sizable Haquira East Cu-Mo deposit in southern Peru, which they eventually sold to First Quantum for $650M.

Spanish Mountain Gold Ltd – Mining Monthly: September Edition

By Atrium Research

  • What you need to know: • In September, gold rose 10.8% to approach $3,900/oz and silver surged 14.4% toward $46/oz, marking five straight months of gains.
  • • Mining equities strongly outperformed, with GDX, GDXJ, SILJ, and COPX up 20.9%, 23.7%, 23.9%, and 20.1%, respectively, versus the S&P 500 (+3.4%) and TSX (+5.1%).
  • • Sector momentum was reinforced by the Fed rate cut, record financing activity among juniors, and the announcement of the $53B Teck–Anglo American merger, the largest deal in over a decade.

Exploits Discovery Corp – Q3/25 Recap: All Our Research in One Place!

By Atrium Research

  • Q3/25 marked a particularly strong quarter for Atrium, as precious metal prices continued to rise rapidly, driving notable outperformance across our coverage.
  • Our covered stocks increased 46% on average in Q3/25 and are up 227% over the past year, outperforming the TSX, which gained 12% during the quarter and 37% YoY, and TSXV, which gained 29% and 67%, respectively.
  • This builds on the 27% increase from our coverage universe in Q2/25.

Lucror Analytics – Morning Views Asia

By Trung Nguyen

  • In today’s Morning Views publication we comment on developments of the following high yield issuers: JSW Steel
  • UST yields fell yesterday, led by the front end and belly, as weaker than projected ADP employment data further bolstered Fed easing expectations. The UST curve bull steepened, with the yield on the 2Y UST down 7 bps to 3.54%, while that on the 10Y UST declined 5 bps to 4.10%.
  • Equities climbed for the fourth day, with the market remaining upbeat despite the US government shutdown. The S&P 500 and Nasdaq rose 0.3% and 0.4% to 6,711 and 22,755, respectively.

EPM: Latest SCOOP/STACK Acquisition Supports Consistent Dividend Philosophy

By Water Tower Research

  • The SCOOP/STACK mineral and royalty acquisition added high-margin production and future development potential with zero incremental capex.
  • Net production was ~420 Boe/d (54% natural gas, 15% oil, and 31% NGLs) as of the transaction’s effective date on May 1, 2025.
  • Importantly, the only incremental lifting costs associated with the production are gathering and processing fees associated with some of the leases.

Oil futures: Crude slides as oversupply concerns offset geopolitics

By Quantum Commodity Intelligence

  • Crude oil futures were sliding lower Thursday as benchmarks racked up a fourth consecutive retreat of the week, coming amid expectations of a further OPEC+ hike offsetting heightened geopolitical tensions.
  • Front-month Dec25 ICE Brent futures were trading at $64.16/b (2035 BST) versus Wednesday’s settle of $65.35/b, while Nov25 NYMEX WTI was at $60.57/b against a previous close of $61.78/b.
  • Briefings from OPEC+ delegates over the last few days have wiped out the previous week’s healthy gains, with the group now expected to bring back a second tranche of voluntary cuts at a quicker-than-expected pace.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Singapore: Jardine Matheson Holdings, DFI Retail Group Holdings and more

By | Daily Briefs, Singapore

In today’s briefing:

  • Jardine Matheson (JML SP): Additional Office Recycling Speculated
  • Primer: DFI Retail Group Holdings (DFI SP) – Oct 2025


Jardine Matheson (JML SP): Additional Office Recycling Speculated

By David Blennerhassett

  • The prior MO for the Jardines group was never sell your commercial buildings. This year marks a paradigm shift in that line of thinking. 
  • First Hongkong Land (HKL SP) sold nine floors of One Exchange Square to HKEX (388 HK). The first such sale since 1988.
  • Now Mandarin Oriental (MAND SP) is negotiating the sale of “certain office space” at One Causeway Bay. Jardine Matheson (JM SP)‘s NAV discount and implied stub are at 12-month lows/highs.

Primer: DFI Retail Group Holdings (DFI SP) – Oct 2025

By αSK

  • DFI Retail Group is undergoing a significant strategic shift, unlocking capital through divestments (over US$900 million) and returning a substantial portion to shareholders (US$600 million special dividend), signaling confidence in its refined focus.
  • The company’s financial performance is mixed, with 1H2025 underlying profit growth of 39% driven by lower financing costs and strong Health & Beauty segment performance, but this is contrasted by multi-year declines in revenue and net income.
  • The forward outlook is challenging, characterized by intense competition and weak consumer sentiment across key Asian markets, making future growth heavily dependent on the successful expansion of its Health & Beauty footprint and effective cost control.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Micron Technology, Molina Healthcare, FONAR , Vicor Corp, BigBear.ai Holdings , Tesla , Lexaria Bioscience , Evolution Petroleum, Crude Oil, Primo Brands Corporation and more

By | Daily Briefs, United States

In today’s briefing:

  • HBM Stocks Will Keep Running (Micron, SK Hynix), It’s Just the Beginning
  • Firebird Management’s Steve Gorelik’s Molina Healthcare Bull Thesis $MOH
  • FONAR Privatization Proposal: 13% Spread, Potential Price Increase, and Strategic Family Control
  • Primer: Vicor Corp (VICR US) – Oct 2025
  • Primer: BigBear.ai Holdings (BBAI US) – Oct 2025
  • Primer: Tesla (TSLA US) – Oct 2025
  • LEXX: Biodistribution Study Results
  • EPM: Latest SCOOP/STACK Acquisition Supports Consistent Dividend Philosophy
  • Oil futures: Crude slides as oversupply concerns offset geopolitics
  • Primo Brands Stock Collapse: Hidden Turnaround Or Total Meltdown?


HBM Stocks Will Keep Running (Micron, SK Hynix), It’s Just the Beginning

By Nicolas Baratte

  • SK Hynix and Micron stocks were lagging TSMC and Nvidia as it took ~2 years for HBM to suck up enough Commodity DRAM capacity to stabilize the Commodity market
  • That’s now done, we’re just at the beginning of spectacular HBM growth for at least 2 more years. The reasons are known: density increases, speed increases, dies thinner…
  • Stocks: keep or buy Micron and SK Hynix. Samsung remains unattractive imo

Firebird Management’s Steve Gorelik’s Molina Healthcare Bull Thesis $MOH

By Yet Another Value Podcast

Molina Healthcare is a managed care organization specializing in Medicaid plans, with a market share of about 6% of the US population in Medicaid

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


FONAR Privatization Proposal: 13% Spread, Potential Price Increase, and Strategic Family Control

By Special Situation Investments

  • FONAR’s privatization offer at $17.25/share by controlling shareholders has a 13% spread, with potential for a price increase.
  • The company, trading at 5x EBITDA, holds $54m net cash, covering a significant portion of the buyout cost.
  • FONAR’s core diagnostic centers generate 92% of revenue; the unprofitable MRI manufacturing segment is operationally integrated.

Primer: Vicor Corp (VICR US) – Oct 2025

By αSK

  • Vicor is a highly innovative designer and manufacturer of high-density, high-efficiency modular power solutions, positioning it as a key enabler for demanding applications in artificial intelligence (AI), high-performance computing (HPC), automotive, and aerospace.
  • The company’s proprietary technologies and vertical integration provide a technological moat; however, the business faces significant risks from customer concentration, intense competition from larger semiconductor players, and market cyclicality.
  • Financial performance has been volatile, with recent margin compression and analyst downgrades creating uncertainty, yet the company maintains a strong balance sheet and is poised to capitalize on long-term secular growth trends in electrification and data center power demands.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: BigBear.ai Holdings (BBAI US) – Oct 2025

By αSK

  • BigBear.ai is a specialized provider of AI-powered decision intelligence solutions, with a primary focus on the U.S. defense, intelligence, and homeland security sectors. Its established relationships and expertise in these niche markets provide a competitive advantage.
  • The company is in a high-growth industry but faces significant financial headwinds. It has a history of substantial net losses and negative operating cash flow, indicating a high-risk profile. Revenue growth has been inconsistent, with recent quarterly performance showing a year-over-year decline.
  • Future success is heavily dependent on securing large-scale government contracts and successfully expanding into the commercial sector to diversify revenue. The company’s strong balance sheet, with a significant cash position, is intended to fund investments to capture these opportunities, but execution remains a key uncertainty.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Tesla (TSLA US) – Oct 2025

By αSK

  • Tesla remains a leader in the electric vehicle (EV) market, but is facing significant margin pressure from slowing demand and intense competition, particularly from Chinese manufacturers.
  • The company’s future growth and lofty valuation are increasingly dependent on its ambitious pivot to artificial intelligence, robotics, and the successful commercialization of a robotaxi network.
  • While revenue growth has decelerated and profitability has declined in recent quarters, the company’s strong brand, technological lead, and expanding energy division provide a foundation for future opportunities, albeit with high execution risk.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


LEXX: Biodistribution Study Results

By Zacks Small Cap Research

  • Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.
  • It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.
  • DHT offers several attractive features: 1) substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, 2) brain permeation, 3) taste masking & 4) side effect reduction.

EPM: Latest SCOOP/STACK Acquisition Supports Consistent Dividend Philosophy

By Water Tower Research

  • The SCOOP/STACK mineral and royalty acquisition added high-margin production and future development potential with zero incremental capex.
  • Net production was ~420 Boe/d (54% natural gas, 15% oil, and 31% NGLs) as of the transaction’s effective date on May 1, 2025.
  • Importantly, the only incremental lifting costs associated with the production are gathering and processing fees associated with some of the leases.

Oil futures: Crude slides as oversupply concerns offset geopolitics

By Quantum Commodity Intelligence

  • Crude oil futures were sliding lower Thursday as benchmarks racked up a fourth consecutive retreat of the week, coming amid expectations of a further OPEC+ hike offsetting heightened geopolitical tensions.
  • Front-month Dec25 ICE Brent futures were trading at $64.16/b (2035 BST) versus Wednesday’s settle of $65.35/b, while Nov25 NYMEX WTI was at $60.57/b against a previous close of $61.78/b.
  • Briefings from OPEC+ delegates over the last few days have wiped out the previous week’s healthy gains, with the group now expected to bring back a second tranche of voluntary cuts at a quicker-than-expected pace.

Primo Brands Stock Collapse: Hidden Turnaround Or Total Meltdown?

By Baptista Research

  • After shedding 28% of its value year-to-date, Primo Water’s stock has come under intense scrutiny.
  • The sharp decline reflects operational dislocations following its November 2024 merger with BlueTriton Brands, as well as broader disruptions across weather-impacted sales regions and distribution bottlenecks.
  • In Q2 2025, comparable net sales fell 2.5% year-over-year, prompting a downward revision of full-year guidance to flat-to-1% growth from the previously guided 3% to 5%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Molina Healthcare, The United Laboratories International Holdings Limited, FONAR , Innovent Biologics Inc, Astellas Pharma, Lexaria Bioscience , PolyNovo Ltd, D.Western Therapeutics Institute Inc., Veritas In Silico and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Firebird Management’s Steve Gorelik’s Molina Healthcare Bull Thesis $MOH
  • The United Laboratories International Holdings (TUL) Ltd (3933 HK) – Retain Buy
  • FONAR Privatization Proposal: 13% Spread, Potential Price Increase, and Strategic Family Control
  • Primer: Innovent Biologics Inc (1801 HK) – Oct 2025
  • Astellas Pharma (4503 JP): Izervay Approved In Japan, Strategic Brands Will Be Key In Near Future
  • LEXX: Biodistribution Study Results
  • Primer: PolyNovo Ltd (PNV AU) – Oct 2025
  • News Flash – D. Western Therapeutics Institute (4576 JP) – October 2, 2025
  • (30 Sep 2025) Veritas In Silico(130A JP) — Fisco Company Research


Firebird Management’s Steve Gorelik’s Molina Healthcare Bull Thesis $MOH

By Yet Another Value Podcast

Molina Healthcare is a managed care organization specializing in Medicaid plans, with a market share of about 6% of the US population in Medicaid

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


The United Laboratories International Holdings (TUL) Ltd (3933 HK) – Retain Buy

By Avien Pillay

  • Despite its 96% price appreciation since our initiation, United Laboratories is still trading on a 8.7 FPE, and a 5.5 EV/EVITDA.
  • A US FDA GLP-1 approval and a potential $ 1.8bn deal with Novo Nordisk demonstrates its successful diabetes and obesity strategy.
  • With over 80 drugs in the pipeline to be delivered over the next five years, we believe that TUL is about to experience a very material increase in topline growth.

FONAR Privatization Proposal: 13% Spread, Potential Price Increase, and Strategic Family Control

By Special Situation Investments

  • FONAR’s privatization offer at $17.25/share by controlling shareholders has a 13% spread, with potential for a price increase.
  • The company, trading at 5x EBITDA, holds $54m net cash, covering a significant portion of the buyout cost.
  • FONAR’s core diagnostic centers generate 92% of revenue; the unprofitable MRI manufacturing segment is operationally integrated.

Primer: Innovent Biologics Inc (1801 HK) – Oct 2025

By αSK

  • Innovent Biologics is a rapidly growing Chinese biopharmaceutical firm transitioning towards profitability, driven by a strong portfolio of commercialized drugs, notably the PD-1 inhibitor TYVYT® (sintilimab).
  • The company possesses a deep and diversified pipeline spanning oncology, metabolic diseases, autoimmune disorders, and ophthalmology, positioning it for sustained long-term growth beyond its current core products.
  • While exhibiting impressive revenue growth and improving financials, the company faces significant risks from intense domestic competition, government-led drug price negotiations (NRDL), and a high valuation that may already price in future success.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Astellas Pharma (4503 JP): Izervay Approved In Japan, Strategic Brands Will Be Key In Near Future

By Tina Banerjee

  • Astellas Pharma (4503 JP) received a conditional approval of IZERVAY (avacincaptad pegol intravitreal solution) in Japan for the suppression of geographic atrophy (GA) growth in atrophic age-related macular degeneration (AMD).
  • In Q1FY26, with 25% YoY revenue growth, Izervay reported record high quarterly sales of ¥16B. The drug continues to be preferred treatment for new patient start (market share of ~55%).
  • For FY26, Astellas projects revenue of ¥470B from strategic brands, of which Izervay is expected to around ~¥105B. This will gradually accelerate in coming fiscals with Japan sales falling in.

LEXX: Biodistribution Study Results

By Zacks Small Cap Research

  • Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.
  • It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.
  • DHT offers several attractive features: 1) substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, 2) brain permeation, 3) taste masking & 4) side effect reduction.

Primer: PolyNovo Ltd (PNV AU) – Oct 2025

By αSK

  • PolyNovo is a rapidly growing medical device company whose patented NovoSorb® biodegradable polymer technology is disrupting the advanced wound care market, particularly in burns and trauma.
  • The company has demonstrated exceptional revenue growth, recently achieving profitability, driven by the increasing adoption of its flagship product, NovoSorb BTM, in key markets like the United States.
  • Future growth is expected to be fueled by geographic expansion into new markets, the launch of new products and indications (such as NovoSorb MTX), and potential tailwinds from favorable reimbursement changes in the U.S.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


News Flash – D. Western Therapeutics Institute (4576 JP) – October 2, 2025

By Sessa Investment Research

  • DWTI announced after the close on 10/1 that 74.0% of the Series 13 Share Acquisition Rights (with exercise price adjustment clause) issued on July 31, 2025, have already been exercised in just two months since the issue (see table below).
  • In other words, this leaves only 2.6mn shares, or 5.69% dilution remaining.
  • This marks a significant decline in selling pressure going forward, ahead of multiple expected share price catalysts, including 1) China launch of DW-1002 (Brilliant Blue G) for indication ILM staining as an aid for ophthalmic surgeries…

(30 Sep 2025) Veritas In Silico(130A JP) — Fisco Company Research

By FISCO

Key points (machine generated)

  • Veritas In Silico is a Tokyo Stock Exchange-listed company focused on mRNA-targeted pharmaceuticals.
  • The company employs a hybrid business model combining platform-type and pipeline-type approaches for drug discovery.
  • Veritas is researching both small molecule and nucleic acid drugs using its proprietary ibVIS® platform.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: New World Development, The United Laboratories International Holdings Limited, Cosin Solar Technology Co, Innovent Biologics Inc, Sunny Optical Technology Group, Accelink Technologies Co A, FS.COM and more

By | China, Daily Briefs

In today’s briefing:

  • A Contrarian View on New World: Market Is Forward-Looking, Bet on Leveraged Play in Rate Cut Cycle
  • The United Laboratories International Holdings (TUL) Ltd (3933 HK) – Retain Buy
  • Cosin Solar Technology Co Pre-IPO Tearsheet
  • Primer: Innovent Biologics Inc (1801 HK) – Oct 2025
  • Primer: Sunny Optical Technology Group (2382 HK) – Oct 2025
  • Primer: Accelink Technologies Co A (002281 CH) – Oct 2025
  • Pre-IPO FS.COM – The Concerns Behind the Business Model and the Outlook


A Contrarian View on New World: Market Is Forward-Looking, Bet on Leveraged Play in Rate Cut Cycle

By Jacob Cheng

  • New World announced FY25 results, market reaction was initially negative, due to losses to shareholders.  Stock was down 10% post open but rebounded quickly to recover all the losses
  • However, we think the market has neglected the other positives: strong contract sales, resilient IP earnings, improved total debt, stabilized gearing and lower borrow cost
  • Market is forward-looking, we think NWD, as a leveraged play, will benefit the most in rate cut cycle.  At current valuation (0.12x PB) – we continue to stay bullish

The United Laboratories International Holdings (TUL) Ltd (3933 HK) – Retain Buy

By Avien Pillay

  • Despite its 96% price appreciation since our initiation, United Laboratories is still trading on a 8.7 FPE, and a 5.5 EV/EVITDA.
  • A US FDA GLP-1 approval and a potential $ 1.8bn deal with Novo Nordisk demonstrates its successful diabetes and obesity strategy.
  • With over 80 drugs in the pipeline to be delivered over the next five years, we believe that TUL is about to experience a very material increase in topline growth.

Cosin Solar Technology Co Pre-IPO Tearsheet

By Hong Jie Seow

  • Cosin Solar Technology Co (SUPCOZ CH) is looking to raise about US$100m in its upcoming Hong Kong IPO. The deal will be run by China Securities International.
  • Cosin Solar Technology Co. (CST) is a Chinese company specializing in concentrated solar power (CSP) solutions, particularly molten salt tower systems. 
  • The company’s main business lies in providing the collector system and other core sub-systems essential for constructing large-scale CSP plants.

Primer: Innovent Biologics Inc (1801 HK) – Oct 2025

By αSK

  • Innovent Biologics is a rapidly growing Chinese biopharmaceutical firm transitioning towards profitability, driven by a strong portfolio of commercialized drugs, notably the PD-1 inhibitor TYVYT® (sintilimab).
  • The company possesses a deep and diversified pipeline spanning oncology, metabolic diseases, autoimmune disorders, and ophthalmology, positioning it for sustained long-term growth beyond its current core products.
  • While exhibiting impressive revenue growth and improving financials, the company faces significant risks from intense domestic competition, government-led drug price negotiations (NRDL), and a high valuation that may already price in future success.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Sunny Optical Technology Group (2382 HK) – Oct 2025

By αSK

  • Sunny Optical is a global leader in optical components, holding substantial market shares in key segments like vehicle and handset lens sets, positioning it to capitalize on long-term growth in automotive autonomy and smartphone premiumization.
  • The company exhibits a strong financial profile, characterized by a healthy net cash position, which provides resilience and flexibility. However, it has faced significant headwinds recently, with key financial metrics showing negative growth over the last three years.
  • Key risks include high customer concentration with major tech companies, intense industry competition, and the rapid pace of technological change, which creates uncertainty and could impact future profitability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Accelink Technologies Co A (002281 CH) – Oct 2025

By αSK

  • Accelink is a leading Chinese optical components manufacturer, well-positioned to capitalize on secular growth trends in data centers, 5G, and AI-driven network upgrades. Strong revenue growth and market momentum are key positives.
  • Significant concern arises from the company’s consistently negative cash flow generation. Despite a strong top-line growth track record, operating and free cash flow have deteriorated significantly over the last several years, indicating potential issues with working capital management or profitability of its growth.
  • The company trades at a premium valuation compared to the provided peer average, with a P/E ratio over 60x. This elevated valuation, combined with margin pressure and severe cash flow issues, suggests the market may be pricing in a level of growth and profitability that could be challenging to achieve.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Pre-IPO FS.COM – The Concerns Behind the Business Model and the Outlook

By Xinyao (Criss) Wang

  • FS adopts a unique light-asset business model of “R&D design + outsourcing production + direct sales platform”, which leads to higher profit margin than traditional channel sales vendors.
  • FS once failed in A-Share IPO and received penalty in 2025. Internal control defects are the “Achilles heel”, which makes us worry whether FS has the problem of “inflating revenue”. 
  • Although FS has positive performance growth, the uncertainty of Sino-US relations and exchange rate risks may put pressure on profitability. Valuation of FS could be lower than peers. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars